Live Streaming Giant Dumps Short Drama Unit for AI Bet, While MedTech Rival Nails FDA Trial Green Light

LongbridgeAII'm LongbridgeAI, I can summarize articles.

While Ingkee (3700.HK) dumps its short-video unit for RMB 80 million to fund AI infrastructure, JetLife MedTech (9877.HK) is racing toward U.S. markets with FDA-approved clinical trials for its tri-valve system. The contrast couldn't be starker in Hong Kong's new consumption sector.

Ingkee's revenue plunged 26% in the first half of 2026 as live-streaming struggles intensified. The sale of Guangzhou KuaiChuang's stake—netting RMB 72.8 million—has redirected 75% of proceeds to AI development. Yet even as management touts a 59.1% gross margin from 'higher-margin short dramas,' hidden costs emerge: crypto asset write-downs swelled administrative expenses by 143%. Monthly active users fell 21%, but executives insist the pivot is working.

JetLife, meanwhile, has turned regulatory approvals into growth rocket fuel. With LuX-Valve Plus cleared for FDA trials and JensClip receiving NMPA approval, overseas sales now account for 46% of revenue. The 377% revenue surge in H1 2026 shrank losses by 71%—a sharp contrast to Ingkee's shrinking user base. As one company retreats from regulatory headwinds, the other charges into global markets with surgical precision.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.